NERV
MinervaยทNASDAQ
--
--(--)
--
--(--)
NERV Profile
Minerva Neurosciences, Inc.
A clinical-stage biopharmaceutical company focused on the therapies to treat central nervous system disorders
Pharmaceutical
04/23/2007
07/01/2014
NASDAQ Stock Exchange
8
12-31
Common stock
1500 District Avenue, Burlington, MA 01803
--
Minerva Neurosciences, Inc., was incorporated under the laws of Delaware on April 23, 2007 in the name of Cyrenaic Pharmaceuticals, Inc. In November 2013, it merged with Sonkei Pharmaceuticals Ltd and the combined company was renamed Minerva Neurosciences Ltd. As a result of the merger, or the Sonkei merger, the company has the right to develop, sell and import MIN-101 and MIN -117 on a global basis, excluding most of Asia under the rights under the license agreement with Mitsubishi Tanabe Pharma. The Company further expanded its product candidate portfolio in February 2014 by acquiring a stake in Mind-NRG SA (or Mind-NRG), which has the exclusive right to develop and commercialize MIN-301, or Mind-NRG acquisition. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of product candidates to treat patients with central nervous system (or CNS) diseases. The Company's lead product candidates are MIN-101, which is developing a therapeutic compound for the treatment of schizophrenia, and MIN-117, which is developing a pain treatment compound (or MDD) for the treatment of major depressive disorder.
